Press Releases CombiGene AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 28/06/2024 BST			5-day change	1st Jan Change
2.9 ^SEK	-5.23%		-6.45%	+7.81%

06-24	CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01	CI
05-27	CombiGene Appoints New Chief Scientific Officer	MT

BioStock: CombiGene positive to new license agreement for CG01	06-26	AQ
Västra Hamnen publishes initial analysis of CombiGene	06-25	AQ
CombiGene enters into a license agreement with Spark for the epilepsy project CG01	06-24	AQ
CombiGene: Preclinical experts in gene therapy	06-20	AQ
CombiGene selects Västra Hamnen Corporate Finance as new Certified Adviser	06-14	AQ
BioStock: She is CombiGene's new CSO	05-31	AQ
CombiGene appoints new Chief Scientific Officer	05-27	AQ
Bulletin from the annual general meeting of CombiGene AB (publ)	05-23	AQ
Interim report January – March 2024 for CombiGene AB (publ)	05-17	AQ
BioStock: CombiGene's pain programme takes important steps forward	05-03	AQ
CombiGene AB (publ) publishes annual report for 2023	04-26	AQ
Notice of Annual General Meeting in CombiGene AB (publ)	04-18	AQ
BioStock: CombiGene's CEO comments on the patent approvals in Australia and India	03-20	AQ
CombiGene’s epilepsy project CG01 has been granted patent in two new countries	03-13	AQ
BioStock: Comments from Orphazyme on the investment in CombiGene	03-04	AQ
The Danish company Orphazyme has acquired 10% of the shares in CombiGene	02-21	AQ
Year-end report January-December 2023 CombiGene AB (Publ)	02-16	AQ
BioStock: CombiGene comments on the discontinued CGT2 project	02-02	AQ
CombiGene discontinues the preclinical development of the lipodystrophy project CGT2	02-01	AQ
CombiGene: "We continue to believe in the epilepsy project CG01"	01-16	AQ

No results for this search